29.30
前日終値:
$30.28
開ける:
$29.72
24時間の取引高:
727.59K
Relative Volume:
1.07
時価総額:
$1.71B
収益:
$32.87M
当期純損益:
$674.31M
株価収益率:
2.5792
EPS:
11.36
ネットキャッシュフロー:
$-330.11M
1週間 パフォーマンス:
-9.32%
1か月 パフォーマンス:
-17.56%
6か月 パフォーマンス:
-34.05%
1年 パフォーマンス:
+0.21%
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
名前
Agios Pharmaceuticals Inc
セクター
電話
617-649-8600
住所
88 SIDNEY STREET, CAMBRIDGE, MA
AGIO を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
AGIO
Agios Pharmaceuticals Inc
|
29.30 | 1.71B | 32.87M | 674.31M | -330.11M | 11.36 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-02-24 | 開始されました | H.C. Wainwright | Buy |
2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
2024-10-10 | 再開されました | Raymond James | Outperform |
2024-09-27 | ダウングレード | Leerink Partners | Outperform → Market Perform |
2024-02-08 | 開始されました | Cantor Fitzgerald | Overweight |
2023-02-03 | 開始されました | Piper Sandler | Overweight |
2022-11-17 | アップグレード | Goldman | Sell → Neutral |
2022-07-27 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
2021-12-03 | 開始されました | BofA Securities | Buy |
2021-07-30 | ダウングレード | Goldman | Neutral → Sell |
2021-07-01 | 開始されました | Raymond James | Mkt Perform |
2021-06-10 | 開始されました | H.C. Wainwright | Buy |
2021-03-01 | ダウングレード | JP Morgan | Overweight → Neutral |
2021-03-01 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
2021-02-26 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
2020-10-22 | アップグレード | Barclays | Equal Weight → Overweight |
2020-03-04 | 開始されました | Barclays | Equal Weight |
2019-11-26 | 開始されました | Cantor Fitzgerald | Overweight |
2019-09-23 | アップグレード | Guggenheim | Neutral → Buy |
2019-05-23 | 再開されました | Goldman | Neutral |
2019-02-15 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
2018-09-25 | 開始されました | Leerink Partners | Mkt Perform |
2018-05-23 | 開始されました | Citigroup | Buy |
2018-04-11 | 繰り返されました | Credit Suisse | Outperform |
2018-02-15 | 繰り返されました | Needham | Buy |
2018-02-15 | 繰り返されました | SunTrust | Buy |
2017-09-15 | 開始されました | RBC Capital Mkts | Outperform |
2017-08-10 | 繰り返されました | Needham | Buy |
2017-08-08 | 繰り返されました | SunTrust | Buy |
2017-08-02 | アップグレード | Leerink Partners | Mkt Perform → Outperform |
2017-06-26 | ダウングレード | Janney | Buy → Neutral |
2017-01-17 | アップグレード | Oppenheimer | Perform → Outperform |
2016-10-24 | 開始されました | Needham | Buy |
2016-06-13 | アップグレード | JP Morgan | Neutral → Overweight |
2016-05-18 | 繰り返されました | SunTrust | Buy |
すべてを表示
Agios Pharmaceuticals Inc (AGIO) 最新ニュース
Is Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) the Best Small Cap Stock to Buy Before They Explode? - Insider Monkey
First Week of November 21st Options Trading For Agios Pharmaceuticals (AGIO) - Nasdaq
Agios Pharmaceuticals divulges new PAH stabilizers for phenylketonuria - BioWorld MedTech
Beta Thalassemia Market Predicted to See Upsurge Through 2034, - openPR
Agios Pharmaceuticals at Barclays Conference: Strategic Advances in Rare Disease Treatments - Investing.com UK
Agios Pharm at Leerink’s Global Healthcare Conference: Strategic Insights By Investing.com - Investing.com Canada
Q1 EPS Estimate for Agios Pharmaceuticals Lowered by Analyst - Defense World
FY2027 Earnings Estimate for AGIO Issued By Zacks Research - Defense World
Agios Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer - The Manila Times
Agios Pharmaceuticals Announces Inducement Equity Awards for New Executive - GuruFocus.com
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate - EIN News
Celldex Therapeutics and Agios Pharmaceuticals to Present at March 2025 Investor Conferences - Barchart
Meet Agios' New Strategy Chief: Inside the $2M+ Executive Compensation Deal - Stock Titan
Agios Pharmaceuticals chief commercial officer sells $59,742 in stock By Investing.com - Investing.com South Africa
Agios Pharmaceuticals chief commercial officer sells $59,742 in stock - Investing.com India
Agios Pharmaceuticals CEO sells shares worth $460,135 - Investing.com
Agios to Present at Upcoming Investor Conferences - The Manila Times
Where to Hear Agios Management Next Month: Key Investor Conferences Revealed - StockTitan
Insmed, Agios rise; DraftKings, Atlantica fall, Tuesday, 5/28/2024 - Star Tribune
Is Agios Pharmaceuticals, Inc. (AGIO) the Best Small-Cap Stock to Buy Now? - Insider Monkey
Y Intercept Hong Kong Ltd Acquires Shares of 45,817 Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat
What is HC Wainwright's Estimate for AGIO Q1 Earnings? - MarketBeat
Earnings call transcript: Agios Pharm Q4 2024 beats EPS forecast, stock rises - MSN
10 Best Small-Cap Stocks to Buy Now - Insider Monkey
Gilbert Cisneros conducts multiple transactions in stocks including Agios Pharmaceuticals and Airbnb - MSN
Sickle Cell Disease Market Growth Projections 2024-2034: - openPR
Q4 Earnings Estimate for AGIO Issued By HC Wainwright - MarketBeat
Venturi Wealth Management LLC Takes Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World
What is HC Wainwright’s Estimate for AGIO Q4 Earnings? - Defense World
Agios Bolsters Coffers With $1.1 Bln Milestone Payments Following FDA Approval Of Vorasidenib - RTTNews
H.C. Wainwright sets $58 target on Agios Pharma stock with Buy rating By Investing.com - Investing.com South Africa
H.C. Wainwright starts Agios Pharmaceuticals coverage with 'buy' - TradingView
H.C. Wainwright sets $58 target on Agios Pharma stock with Buy rating - Investing.com India
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Short Interest Down 6.0% in January - MarketBeat
Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025 - The Manila Times
Why Agios Pharmaceuticals' (NASDAQ:AGIO) Earnings Are Weaker Than They Seem - Simply Wall St
Rare Disease Leader Agios Takes Center Stage at Major Healthcare ConferenceKey Details Inside - StockTitan
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q4 2024 Earnings Call Transcript - MSN
Agios Pharmaceuticals (NASDAQ:AGIO) Downgraded by StockNews.com to "Sell" - MarketBeat
Agios' Q4 Loss Wider Than Expected, Pyrukynd Drives Revenues - MSN
Agios Pharmaceuticals (NASDAQ: AGIO) Board Member Resignation: David P. Schenkein Steps Down - Defense World
Here's Why Agios Stock Plummeted More Than 20% on Monday - MSN
Agios (AGIO) Q1 Earnings Surpass, Sales Miss Estimates - MSN
Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Tops Revenue Estimates - MSN
Agios Pharmaceuticals price target lowered to $74 from $75 at Scotiabank - Yahoo Finance
Agios Pharmaceuticals announces board resignation - MSN
Long Term Trading Analysis for (AGIO) - Stock Traders Daily
Agios Pharmaceuticals: Liver Toxicity Issues May Threaten Thalassemia Approval (Rating Downgrade) - Seeking Alpha
Agios Pharmaceuticals Inc (AGIO) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):